A clinical stage biotech company focusing on cell energy metabolism

Enhanced Mitochondrial and Lysosomal function by up-regulation of PGC-1a and TFEB

Small molecules T-168 and T-621 for oral administration

 → T-168 is in clinical phase 2 for neurodegenerative and metabolic diseases

→ T-168 has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial with funding from Cure Parkinson’s, the Norwegian Parkinson’s Research Fund, the Norwegian Parkinson’s Association and Haukeland University (Norway)

 
→ T-621 is in IND enabling studies

Our MOA is relevant across indications in neuro, metabolic, 
cardiovascular, liver, kidney, and muscle diseases.

We are actively seeking pharma partners and early-stage investors to unlock the
broad potential of PGC-1α and TFEB up-regulation in neurodegeneration, aging and metabolic disease areas.

LEADERSHIP
Frederic Godderis, MS → founder | ceo | director
Enchi Liu, PhD → co-founder | chief development officer
Andrew Lam, MS → co-founder | chief technology officer
Saira Ramasastry, MS → corporate development lead

ADVISORS
Edgar Engleman, MD, PhD → scientific founder | Prof. of Pathology and Medicine | Vivo Capital | Stanford University, USA
Charalampos Tzoulis, MD, PhD → Prof. of Neurology & Neurogenetics | University of Bergen, Norway
Sanjay Kakkar, MD → founder | director | former chairperson of Tranquis Therapeutics and ceo of Tensive SRL | Milan, Italy